Zantac 150

Zollinger-Ellison Syndrome, Curling Ulcer, Heartburn + 24 more

Treatment

31 FDA approvals

20 Active Studies for Zantac 150

What is Zantac 150

Ranitidine

The Generic name of this drug

Treatment Summary

Ranitidine is a medication used to reduce the amount of acid in the stomach. It is classified as an H2-receptor antagonist, which means it works by blocking histamine from increasing the acid production. Ranitidine is known by the brand name Zantac, and can be taken in the form of a tablet, injection, or effervescent tablet. This drug is commonly used to treat and prevent conditions caused by too much stomach acid, such as ulcers and gastroesophageal reflux disease (GERD). Ranitidine has been found to be an effective treatment for relieving GERD symptoms, which

Zantac

is the brand name

image of different drug pills on a surface

Zantac 150 Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zantac

Ranitidine

1983

592

Approved as Treatment by the FDA

Ranitidine, also known as Zantac, is approved by the FDA for 31 uses which include Duodenal Ulcer and Gastric Ulcer .

Duodenal Ulcer

Gastric Ulcer

Used to treat Gastric Ulcer in combination with Almasilate

Ankylosing Spondylitis (AS)

Used to treat Ankylosing Spondylitis (AS) in combination with Capsicum oleoresin

active Duodenal ulcer

Heartburn

prophylaxis of Heartburn

benign gastric ulcers

Used to treat benign gastric ulcers in combination with Almasilate

Osteoarthritis (OA)

Used to treat Osteoarthritis (OA) in combination with Capsicum oleoresin

Systemic Mastocytosis

Helps manage Systemic Mastocytosis

Gastro-esophageal Reflux Disease (GERD)

Duodenal Ulcer

Esophagus

Gastric ulcer

Used to treat benign gastric ulcers in combination with Almasilate

Heartburn

Osteoarthritis

Used to treat Osteoarthritis (OA) in combination with Capsicum oleoresin

Erosive Esophagitis

Curling Ulcer

Healing

Rheumatoid Arthritis

Used to treat Rheumatoid Arthritis in combination with Capsicum oleoresin

Ankylosing Spondylitis

Used to treat Ankylosing Spondylitis (AS) in combination with Capsicum oleoresin

prophylaxis of Stress Ulcers

Stomach Ulcer

Used to treat Gastric Ulcer in combination with Almasilate

Stress Ulcers

Heartburn

Serious Illness

Zollinger-Ellison Syndrome

Helps manage Zollinger-Ellison Syndrome

Peptic Ulcer Disease

Gastric hypersecretion

Helps manage Gastric hypersecretion

benign gastric ulcer healing

Heartburn

Mastocytosis, Systemic

Helps manage Systemic Mastocytosis

Effectiveness

How Zantac 150 Affects Patients

Ranitidine works to reduce the amount of acid created in the stomach, whether it is due to food or other drugs. It is often used to treat Zollinger-Ellison syndrome, a condition that causes too much stomach acid. After taking ranitidine, endoscopic imaging has shown that the tissue in the esophagus has improved.

How Zantac 150 works in the body

Ranitidine works by blocking histamine receptors in the stomach, which helps reduce the production of stomach acid. It only takes about an hour for it to start working, and it can provide relief for up to 10 hours.

When to interrupt dosage

The prescribed dosage of Zantac 150 hinges upon the determined condition, such as benign gastric ulcer healing, Erosive Esophagitis and Heartburn. The measure of dosage is contingent upon the approach of delivery (e.g. Intramuscular; Intravenous or Capsule) as outlined in the table beneath.

Condition

Dosage

Administration

Heartburn

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Erosive Esophagitis

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Rheumatoid Arthritis

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Osteoarthritis

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Serious Illness

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Zollinger-Ellison Syndrome

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Duodenal Ulcer

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Heartburn

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Curling Ulcer

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Healing

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Gastric ulcer

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Gastric hypersecretion

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Peptic Ulcer Disease

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Stomach Ulcer

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Mastocytosis, Systemic

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

benign gastric ulcer healing

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Heartburn

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Esophagus

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

prophylaxis of Stress Ulcers

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

General Anesthesia

150.0 mg, , 75.0 mg, 300.0 mg, 15.0 mg/mL, 75.0 mg/mL, 25.0 mg/mL, 150.0 mg/mL, 400.0 mg, 25.0 mg, 5.0 mg/mL, 84.0 mg, 4.2 mg/mg, 6.4 mg/mg, 50.0 mg/mL

Tablet, film coated - Oral, , Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Syrup - Topical, Topical, Syrup, Syrup - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, Injection - Intramuscular; Intravenous, Kit, Liquid - Intramuscular; Intravenous, Liquid, Solution - Intramuscular; Intravenous, Tablet, effervescent - Oral, Tablet, effervescent, Intravenous, Injection, solution - Intravenous, Kit - Oral, Oral; Topical, Kit - Oral; Topical

Warnings

Zantac 150 Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Ranitidine may interact with Pulse Frequency

There are 20 known major drug interactions with Zantac 150.

Common Zantac 150 Drug Interactions

Drug Name

Risk Level

Description

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Ranitidine.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Ranitidine.

Atazanavir

Major

Ranitidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.

Cefpodoxime

Major

Ranitidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.

Cefuroxime

Major

Ranitidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.

Zantac 150 Toxicity & Overdose Risk

In tests, mice and rats were not harmed after being given a dose of 1,000mg/kg orally. Mice and rats given an intravenous dose of 77 and 83mg/kg respectively died. People who have taken too much ranitidine may experience abnormal heart rate, dizziness, diarrhea, nausea, vomiting, and other symptoms. They may also be unsteady on their feet and have low blood pressure. If an overdose is suspected, any unabsorbed ranitidine should be removed from the stomach and the patient should be monitored and given supportive care.

image of a doctor in a lab doing drug, clinical research

Zantac 150 Novel Uses: Which Conditions Have a Clinical Trial Featuring Zantac 150?

85 clinical trials are presently in progress to evaluate the potential of Zantac 150 to address Peptic Ulcer Disease, Hemorrhage and Gastric ulceration.

Condition

Clinical Trials

Trial Phases

Duodenal Ulcer

0 Actively Recruiting

Heartburn

2 Actively Recruiting

Phase 3, Not Applicable

Curling Ulcer

0 Actively Recruiting

Gastric hypersecretion

0 Actively Recruiting

Stomach Ulcer

2 Actively Recruiting

Phase 4, Not Applicable

Mastocytosis, Systemic

0 Actively Recruiting

Erosive Esophagitis

2 Actively Recruiting

Phase 2, Phase 3

Heartburn

0 Actively Recruiting

Gastric ulcer

0 Actively Recruiting

Zollinger-Ellison Syndrome

0 Actively Recruiting

General Anesthesia

1 Actively Recruiting

Phase 4

Healing

0 Actively Recruiting

Ulcer

0 Actively Recruiting

Osteoarthritis

0 Actively Recruiting

Esophagus

0 Actively Recruiting

Rheumatoid Arthritis

55 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

prophylaxis of Stress Ulcers

0 Actively Recruiting

Stress Ulcers

0 Actively Recruiting

Ankylosing Spondylitis

3 Actively Recruiting

Phase 3, Not Applicable

Heartburn

12 Actively Recruiting

Phase 3, Phase 2, Not Applicable

Zantac 150 Reviews: What are patients saying about Zantac 150?

5

Patient Review

6/7/2010

Zantac 150 for Condition in which Stomach Acid is Pushed Into the Esophagus

This medication has been great for controlling my acid reflux. I was originally put on it due to stress from work and life, but it's helped me out a lot. There are occasional times when it doesn't work as well as I'd like, but it's still better than nothing.

5

Patient Review

10/16/2007

Zantac 150 for Condition in which Stomach Acid is Pushed Into the Esophagus

5

Patient Review

3/27/2013

Zantac 150 for Heartburn

This medicine was great! I didn't experience any negative side effects, and it really helped me feel better.

4.3

Patient Review

3/18/2009

Zantac 150 for Condition in which Stomach Acid is Pushed Into the Esophagus

4

Patient Review

5/26/2010

Zantac 150 for Condition in which Stomach Acid is Pushed Into the Esophagus

My doctor says this drug interferes with my platelet count. Is this true? It works good for my stomach problems.

3

Patient Review

5/4/2010

Zantac 150 for Inflammation of the Esophagus with Erosion

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zantac 150

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Zantac 150 mg used for?

"This medication works by reducing the amount of acid in your stomach in order to prevent and treat heartburn and other symptoms that are caused by too much acid in the stomach (acid indigestion)."

Answered by AI

What is Zantac 150mg?

"It works by decreasing the amount of acid your stomach makes.

ulcers in the stomach and intestines can be treated and prevented from recurring with ranitidine. It can also be used to ease certain stomach and throat problems like erosive esophagitis and gastroesophageal reflux disease. This medication works by reducing the level of acid in the stomach."

Answered by AI

Is Zantac 150 recalled?

"The FDA has announced that American Health Packaging is voluntarily recalling their ranitidine tablets (150 mg) because they may contain unacceptable levels of N-nitrosodimethylamine (NDMA)."

Answered by AI

How long does Zantac 150 take to work?

"The drug can start working in as little as 30 minutes, controlling acid production for up to 12 hours and reducing the frequency and severity of heartburn. Zantac, made with ranitidine, was traditionally used to treat a variety of gastrointestinal disorders, including heartburn, GERD and gastric ulcers."

Answered by AI

Clinical Trials for Zantac 150

Have you considered Zantac 150 clinical trials?

We made a collection of clinical trials featuring Zantac 150, we think they might fit your search criteria.
Go to Trials
Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada

People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What the Investigators Think: The investigators believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What the Investigators are Doing: The investigators will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing the investigators will look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. The investigators will also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: The investigators have already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. The investigators have also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, the investigators need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.

Phase 4
Waitlist Available

Sunnybrook Health Sciences Centre (+4 Sites)

Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY

The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention

Recruiting
Has No Placebo

Weill Cornell Medical College

Iris Y Navarro-Millán, MD

Bristol-Myers Squibb

Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY

The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.

Waitlist Available
Has No Placebo

Humana Healthcare Research, Inc. (+1 Sites)

Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY

The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.

Phase 1 & 2
Waitlist Available

Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)

Gavin Solomon, President & CEO

Truway Health, Inc.

Have you considered Zantac 150 clinical trials?

We made a collection of clinical trials featuring Zantac 150, we think they might fit your search criteria.
Go to Trials
Image of University of California, Irvine - UCI Medical Center in Orange, United States.

Sling-Fiber Preservation vs. Conventional POEM for Achalasia

18+
All Sexes
Orange, CA

Peroral endoscopic myotomy (POEM) is an effective, minimally invasive treatment for achalasia, offering excellent rates of symptom relief. However, a significant drawback is the high incidence of gastroesophageal reflux disease (GERD) following the procedure. One proposed technical modification, the selective preservation of the sling fibers during gastric myotomy (SFP-POEM), may reduce this risk without compromising efficacy as compared to a conventional POEM procedure, which includes myotomy of the sling fibers. In this study, adults with achalasia will be randomly assigned to receive one of the two POEM technical approaches. Researchers will monitor whether preserving sling fibers reduces the rates of reflux esophagitis (classified as Los Angeles Grade B or higher) on follow-up endoscopy. Participants will be followed for up to 1 year after the procedure.

Waitlist Available
Has No Placebo

University of California, Irvine - UCI Medical Center

Jason Samarasena, MD, MBA

Image of University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases in Minneapolis, United States.

Ultrasound Therapy for Rheumatoid Arthritis

18+
All Sexes
Minneapolis, MN

The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs). The non-invasive study device delivers ultrasound stimulation to the spleen to reduce inflammation. The study will enroll at least 60 participants at up to 8 sites. There will be three arms consisting of two active stimulation groups (treatment) and one non-active stimulation group (sham-control). After completing the double-blinded primary endpoint assessment period at Week 12, there will be a one-way crossover of control participants to active stimulation and an additional 12 week follow-up with all participants to evaluate long-term outcomes.

Recruiting
Drug

University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases (+4 Sites)

Daniel Zachs

SecondWave Systems Inc.

Have you considered Zantac 150 clinical trials?

We made a collection of clinical trials featuring Zantac 150, we think they might fit your search criteria.
Go to Trials